Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatophepatitis

Matthew J Armstrong, Diana Hull, Kathy Guo, Darren Barton, Jonathan M Hazlehurst, Laura L Gathercole, Maryam Nasiri, Jinglei Yu, Stephen C Gough, Philip N Newsome, Jeremy W Tomlinson

Research output: Contribution to journalArticlepeer-review

169 Citations (Scopus)
217 Downloads (Pure)


OBJECTIVE: Insulin resistance and lipotoxicity are pathognomonic in non-alcoholic steatohepatitis (NASH). Glucagon-like peptide-1 (GLP-1) analogues are licensed for type 2 diabetes, but no prospective experimental data exists in NASH. This study determined the effect of a long-acting GLP-1 analogue, liraglutide, on organ-specific insulin sensitivity, hepatic lipid handling and adipose dysfunction in biopsy-proven NASH.

DESIGN: 14 patients were randomised to 1.8mg liraglutide or placebo for 12-weeks of the mechanistic component of a double-blind, randomized, placebo-controlled trial ( Patients underwent paired hyperinsulinaemic euglycaemic clamps, stable isotope tracers, adipose microdialysis and serum adipocytokine/metabolic profiling. In vitro isotope experiments on lipid flux were performed on primary human hepatocytes.

RESULTS: Liraglutide reduced BMI (-1.9 vs. +0.04 kg/m2;p<0.001), HbA1c (-0.3 vs. +0.3%;p<0.01), cholesterol-LDL (-0.7 vs. +0.05 mmol/L;p<0.01), ALT (-54 vs -4.0 IU/L;p<0.01) and serum leptin, adiponectin, and CCL-2 (all p<0.05). Liraglutide increased hepatic insulin sensitivity (-9.36 vs. -2.54% suppression of hepatic endogenous glucose production with low-dose insulin;p<0.05). Liraglutide increased adipose tissue insulin sensitivity enhancing the ability of insulin to suppress lipolysis both globally (-24.9 vs. +54.8 pmol/L insulin required to ½ maximally suppress serum NEFA; p<0.05), and specifically within subcutaneous adipose tissue (p<0.05). In addition, liraglutide decreased hepatic DNL in-vivo (-1.26 vs. +1.30%; p<0.05); a finding endorsed by the effect of GLP-1 receptor agonist on primary human hepatocytes (24.6% decrease in lipogenesis vs. untreated controls; p<0.01).

CONCLUSIONS: Liraglutide reduces metabolic dysfunction, insulin resistance and lipotoxicity in the key metabolic organs in the pathogenesis of NASH. Liraglutide may offer the potential for a disease-modifying intervention in NASH.

Original languageEnglish
Pages (from-to)399–408
Number of pages10
JournalJournal of Hepatology
Issue number2
Early online date21 Sept 2015
Publication statusPublished - Feb 2016


  • Glucagon-like peptide 1
  • Non-alcoholic fatty liver
  • Insulin sensitivity
  • Adipose tissue
  • Lipolysis


Dive into the research topics of 'Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatophepatitis'. Together they form a unique fingerprint.

Cite this